A twelve-week clinical trial investigating a specialized nutritional formulation of beta-glucan, broccoli extract, and quercetin has shown meaningful improvements in respiratory symptoms and functional health status among patients with stable chronic obstructive pulmonary disease. The randomized, double-blind, placebo-controlled study, conducted by an international research team from Chulalongkorn University, Police General Hospital, and Universiti Malaya, evaluated whether an optimized plant-derived combination could mitigate the clinical burden of chronic obstructive pulmonary disease. While the dietary supplement produced measurable symptom relief on standardized clinical scales, the investigators reported that it did not lead to significant changes in primary lung function measurements or circulating inflammatory and oxidative stress biomarkers.
Chronic obstructive pulmonary disease represents a progressive and debilitating respiratory condition defined by persistent airflow limitation, ongoing chronic inflammation, and systemic oxidative stress. Over time, these pathological drivers contribute to cumulative functional impairment, progressive shortness of breath, and a diminished overall quality of life for affected patients. Although beta-glucan is widely recognized in pharmacological research for possessing distinct immunomodulatory and anti-inflammatory properties, its potential therapeutic utility in the management of chronic obstructive pulmonary disease has remained poorly defined. In an effort to address this therapeutic uncertainty, investigators developed and evaluated Pro β-Glucan+, a defined combination combining beta-glucan with broccoli extract and the flavonoid quercetin.
Prior to administering the mixture to human participants, the researchers conducted preclinical laboratory evaluations to determine the most biologically active ratio of the three constituent compounds. Using cultured HFL1 human lung fibroblasts, the research team performed both cell viability assays and in vitro scratch wound healing assays across various formulation proportions. Through these cellular screens, the investigators identified a specific 10:3:2 ratio—corresponding to ten parts beta-glucan, three parts broccoli extract, and two parts quercetin—that significantly enhanced HFL1 cell viability and accelerated cellular wound healing activity compared to alternative mixtures. Based on these observed laboratory results, this specific 10:3:2 formulation was selected for subsequent human clinical testing.
The clinical phase of the investigation was designed as a randomized, double-blind, placebo-controlled trial registered under ClinicalTrials.gov identifier NCT05878834. The study enrolled a total of 42 adult participants diagnosed with stable chronic obstructive pulmonary disease. Over the course of the 12-week intervention schedule, four participants discontinued the protocol, leaving 38 individuals who successfully completed the study and were included in the final data analysis. These completing participants were divided evenly between the two study arms, with 19 participants receiving the optimized active Pro β-Glucan+ formulation and 19 participants receiving an identical matching placebo.
To evaluate physiological changes in respiratory capacity, the investigators prespecified forced expiratory volume in one second, commonly known as FEV1, as the primary clinical outcome of the trial. At the completion of the 12-week protocol, analysis of the spirometric data revealed no statistically significant differences in FEV1 within either study group from baseline. Furthermore, comparisons between the active treatment group and the placebo cohort demonstrated no significant between-group divergence in lung airflow measurements, indicating that the three-month nutritional intervention did not reverse or alter objective airflow obstruction.
In addition to physiological spirometry, the research protocol systematically monitored circulating biomarkers to assess underlying biological mechanisms. The investigators tracked a panel of secondary biological markers specifically tied to systemic inflammation and systemic oxidative stress across all participants. Consistent with the spirometry findings, the laboratory evaluations demonstrated no statistically significant within-group changes or between-group differences in systemic inflammatory biomarkers or oxidative stress biomarkers after 12 weeks of daily administration, suggesting that the clinical effects occurred without broad alterations in measured circulating markers.
Despite the lack of measurable shifts in airflow velocity and systemic blood markers, the trial identified significant benefits across several prespecified patient-reported secondary outcomes. Participants who received Pro β-Glucan+ experienced statistically significant within-group improvements across functional capacity, dyspnea, general respiratory symptoms, and overall health status at the 12-week mark. Most notably, direct comparisons against the placebo group revealed statistically significant between-group differences at week 12 in both modified Medical Research Council dyspnea scores and COPD Assessment Test scores, reflecting meaningful reductions in breathlessness and overall symptom burden.
Secondary outcome assessments also indicated that overall patient satisfaction was higher among individuals assigned to the active supplement group compared to those in the placebo arm.
Subject of Research: Evaluation of an optimized beta-glucan formulation for stable chronic obstructive pulmonary disease
Article Title: Effects of an optimized beta-glucan–based formulation on symptoms, functional capacity, and systemic inflammation in patients with COPD: a randomized controlled trial
Article References: Napavichayanun, S., Yamdech, R., Cherdchom, S., Suriyakul, A., Phetngam, T., Mahmood, S., & Aramwit, P. (2026). Effects of an optimized beta-glucan–based formulation on symptoms, functional capacity, and systemic inflammation in patients with COPD: a randomized controlled trial. Frontiers in Pharmacology, 17, Article 1938897. https://doi.org/10.3389/fphar.2026.1938897
Image Credits: AI Generated
DOI: 10.3389/fphar.2026.1938897
Keywords: chronic obstructive pulmonary disease, beta-glucan, broccoli extract, quercetin, Pro β-Glucan+, HFL1 lung fibroblasts, cell viability assay, wound healing assay, FEV1, mMRC score, CAT score, functional capacity, systemic inflammation, oxidative stress biomarkers, patient satisfaction, adjunctive nutritional intervention, randomized controlled trial
News Source: Ophelia Keating. (November 17, 2026). Beta-Glucan Formulation Eases COPD Symptoms Without Improving Lung Function. Scienmag.



